Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Company Deals

InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform

Fineline Cube Jan 10, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026
Company Drug

Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery

Fineline Cube Nov 1, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...

Company Drug

Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection

Fineline Cube Nov 1, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...

Company Drug

Shenzhen Chipscreen Biosciences Gets NMPA Approval for Phase I Study of CS32582 in Psoriasis

Fineline Cube Nov 1, 2023

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced that it...

Company Deals

Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round

Fineline Cube Nov 1, 2023

Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million)...

Company Deals

ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development

Fineline Cube Nov 1, 2023

ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100...

Company Drug

Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study

Fineline Cube Nov 1, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...

Company Drug

Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Nov 1, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...

Company

Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report

Fineline Cube Nov 1, 2023

US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for...

Company Drug

Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment

Fineline Cube Nov 1, 2023

The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...

Company Deals

AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib

Fineline Cube Nov 1, 2023

China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...

Company Drug

Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial

Fineline Cube Nov 1, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...

Company Deals

BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences

Fineline Cube Nov 1, 2023

Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based...

Drug

Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion

Fineline Cube Nov 1, 2023

Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...

Policy / Regulatory

Guangxi HSA Expands Coverage for Assisted Reproductive Medical Services Under BMI

Fineline Cube Nov 1, 2023

The Healthcare Security Administration (HSA) bureau of the Guangxi Zhuang Autonomous Region has announced a...

Company Medical Device

Siyi Intelligence Secures Approval for Innovative Rehabilitation Robots in China

Fineline Cube Nov 1, 2023

Shanghai-based Siyi Intelligence, a developer of soft rehabilitation robots, has announced that it has received...

Company Deals

Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals

Fineline Cube Nov 1, 2023

China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with...

Company Deals

Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform

Fineline Cube Oct 31, 2023

Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive...

Company Deals

Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor

Fineline Cube Oct 31, 2023

Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with...

Company Drug

Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Oct 31, 2023

Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...

Company Drug

Staidson Receives NMPA Approval for Clinical Trial of STSA-1301 in Primary Immune Thrombocytopenia

Fineline Cube Oct 31, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...

Posts pagination

1 … 391 392 393 … 606

Recent updates

  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
  • Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy
  • RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo
  • Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.